Here is at least one take ($$; subs. req.), on what to expect tomorrow, bright and early:
. . . .Large-cap pharmaceutical giant Merck is scheduled to report earnings before the bell on Tuesday. Analyst consensus is looking for EPS of 75 cents per share vs. 74 cents last year, for year-over growth of 1%, and revenue of $11.175 billion vs. pre-Schering-Plough merger revenue of $5.4 billion. As you can see from the numbers, the Schering-Plough acquisition has doubled revenue, but earnings have not risen commensurately, so 2010 will likely be all about management's ability to reduce costs, improve margins, integrate the Schering pipeline and product line into Merck's portfolio, as well as continue to drive R&D at Merck. . . .
Indeed. And I'll likely live blog it all, tomorrow -- right here. See you around 8:15 a.m. E.D.T., Tuesday.
No comments:
Post a Comment